Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 09, 2021 08:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Announces Upcoming Oral Presentation of Phase 1 Study of NGM621 in Patients with Geographic Atrophy at Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition

--Humanized IgG1 monoclonal antibody engineered to potently inhibit complement C3, with the potential for extended every eight-week dosing-- --CATALINA Phase 2 study of NGM621 in patients with...
January 12, 2021 16:05 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Outlines 2021 Strategic Priorities Across Its Three Therapeutic Area Portfolios, Including Liver and Metabolic Diseases, Retinal Diseases and Oncology

NGM advances its vision to build the next iconic biologics company, fueled by its in-house discovery engineSignificant progress made across all three therapeutic area portfolios in 2020Phase 2b or...
January 05, 2021 21:55 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Announces Pricing of Upsized $125.0 Million Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
January 04, 2021 16:01 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Announces Proposed Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
December 09, 2020 16:05 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Discloses Third Oncology Development Candidate, NGM438, a Novel Antagonist Antibody Inhibiting LAIR1 for the Treatment of Advanced Solid Tumors

LAIR1, through interactions with tumor-associated collagens, may form a stromal checkpoint that imposes signaling-based immune suppression and impedes anti-tumor immunityNGM plans to initiate...
November 16, 2020 12:05 ET | Source: NGM Biopharmaceuticals, Inc.

NGM to Host Virtual R&D Day on December 9, 2020

– Event to showcase NGM’s multi-therapeutic area pipeline, including its oncology portfolio and Geographic Atrophy and NASH programs – – Planned presentations from NGM management, NGM scientists...
November 13, 2020 08:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Presents Phase 1 Safety and Pharmacokinetics Data for NGM621, an Anti-Complement C3 Antibody, in Patients with Geographic Atrophy at the American Academy of Ophthalmology 2020 Virtual

--Single and multiple intravitreal injections of NGM621 appeared safe and well tolerated in first-in-human study, with no patients experiencing serious adverse events, drug-related AEs, intraocular...
November 12, 2020 16:05 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio Provides Business Highlights and Reports Third Quarter 2020 Financial Results

NGM continues to demonstrate the productivity of its research discovery engine and progress against its multi-therapeutic area pipeline: -- Initiated a Phase 2 clinical trial of NGM621, an...
November 11, 2020 08:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio to Present at Three Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
November 05, 2020 08:00 ET | Source: NGM Biopharmaceuticals, Inc.

NGM Bio to Present Safety and Pharmacokinetics Data from Phase 1 Study of NGM621 in Patients with Geographic Atrophy at American Academy of Ophthalmology (AAO) 2020 Virtual

--Humanized IgG1 monoclonal antibody engineered to potently inhibit complement C3, with the potential for extended every eight-week dosing without pegylation-- --Phase 2 (CATALINA) study of...